Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DMRA NASDAQ:GLSI NASDAQ:INBX NASDAQ:PGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$22.37-2.5%$24.98$2.45▼$38.33$1.41B1.46383,264 shs318,625 shsGLSIGreenwich LifeSciences$24.29$25.04$7.78▼$34.10$356.53M1.4143,966 shs121,224 shsINBXInhibrx Biosciences$95.22+1.7%$96.67$12.80▼$155.29$1.37B3.31488,111 shs328,004 shsPGENPrecigen$3.81-1.3%$4.04$1.30▼$5.47$1.38B1.064.25 million shs7.79 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock-7.65%-11.36%-9.50%-22.68%+617.19%GLSIGreenwich LifeSciences-14.80%-10.76%+2.49%-10.04%+151.97%INBXInhibrx Biosciences-5.70%-12.37%-27.30%+25.46%+622.45%PGENPrecigen-6.31%-8.96%-5.39%+8.73%+190.23%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDMRADamora Therapeutics, Inc. Common Stock$22.37-2.5%$24.98$2.45▼$38.33$1.41B1.46383,264 shs318,625 shsGLSIGreenwich LifeSciences$24.29$25.04$7.78▼$34.10$356.53M1.4143,966 shs121,224 shsINBXInhibrx Biosciences$95.22+1.7%$96.67$12.80▼$155.29$1.37B3.31488,111 shs328,004 shsPGENPrecigen$3.81-1.3%$4.04$1.30▼$5.47$1.38B1.064.25 million shs7.79 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDMRADamora Therapeutics, Inc. Common Stock-7.65%-11.36%-9.50%-22.68%+617.19%GLSIGreenwich LifeSciences-14.80%-10.76%+2.49%-10.04%+151.97%INBXInhibrx Biosciences-5.70%-12.37%-27.30%+25.46%+622.45%PGENPrecigen-6.31%-8.96%-5.39%+8.73%+190.23%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDMRADamora Therapeutics, Inc. Common Stock 2.89Moderate Buy$42.0087.75% UpsideGLSIGreenwich LifeSciences 2.33Hold$47.5090.00% UpsideINBXInhibrx Biosciences 2.33Hold$150.0061.64% UpsidePGENPrecigen 2.33Hold$12.50233.78% UpsideCurrent Analyst Ratings BreakdownLatest GLSI, PGEN, DMRA, and INBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2026DMRADamora Therapeutics, Inc. Common Stock WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$35.005/28/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$11.00 ➝ $14.005/15/2026GLSIGreenwich LifeSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/14/2026PGENPrecigen HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $11.005/14/2026PGENPrecigen CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/14/2026PGENPrecigen Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$9.00 ➝ $11.004/24/2026DMRADamora Therapeutics, Inc. Common Stock Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$40.004/24/2026INBXInhibrx Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy4/23/2026DMRADamora Therapeutics, Inc. Common Stock Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy4/21/2026PGENPrecigen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/9/2026INBXInhibrx Biosciences Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold(Data available from 6/3/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/A($110.11) per shareN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/A$0.19 per shareN/AINBXInhibrx Biosciences$1.30M1,047.21N/AN/A$0.55 per share168.73PGENPrecigen$31.60M42.26N/AN/A$0.06 per share62.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDMRADamora Therapeutics, Inc. Common Stock-$209.84M-$5.58N/AN/AN/AN/A-428.30%-114.62%8/5/2026 (Estimated)GLSIGreenwich LifeSciences-$15.79M-$1.46N/AN/AN/AN/A-1,042.84%-565.43%N/AINBXInhibrx Biosciences-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%8/12/2026 (Estimated)PGENPrecigen-$250.64M-$1.18N/A11.01N/A-646.99%717.50%58.48%8/11/2026 (Estimated)Latest GLSI, PGEN, DMRA, and INBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026INBXInhibrx Biosciences-$1.6750-$2.15-$0.4750-$2.15N/AN/A5/13/2026Q1 2026DMRADamora Therapeutics, Inc. Common Stock-$0.3878-$0.62-$0.2322-$0.62N/AN/A5/13/2026Q1 2026PGENPrecigen-$0.03-$0.02+$0.01-$0.02$20.81 million$23.25 million3/25/2026Q4 2025PGENPrecigen-$0.10-$0.01+$0.09-$0.01$8.29 million$4.57 million3/19/2026Q4 2025INBXInhibrx Biosciences-$2.08-$2.11-$0.03-$2.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthDMRADamora Therapeutics, Inc. Common StockN/AN/AN/AN/AN/AGLSIGreenwich LifeSciencesN/AN/AN/AN/AN/AINBXInhibrx BiosciencesN/AN/AN/AN/AN/APGENPrecigenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDMRADamora Therapeutics, Inc. Common StockN/A22.4922.48GLSIGreenwich LifeSciencesN/A2.352.35INBXInhibrx Biosciences12.586.466.46PGENPrecigen4.624.824.12Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDMRADamora Therapeutics, Inc. Common Stock14.20%GLSIGreenwich LifeSciences4.16%INBXInhibrx Biosciences82.46%PGENPrecigen33.51%Insider OwnershipCompanyInsider OwnershipDMRADamora Therapeutics, Inc. Common Stock0.40%GLSIGreenwich LifeSciences51.47%INBXInhibrx Biosciences18.26%PGENPrecigen47.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDMRADamora Therapeutics, Inc. Common Stock4061.55 million61.31 millionNo DataGLSIGreenwich LifeSciences313.85 million6.72 millionNot OptionableINBXInhibrx Biosciences16614.67 million11.99 millionOptionablePGENPrecigen190356.51 million188.59 millionOptionableGLSI, PGEN, DMRA, and INBX HeadlinesRecent News About These CompaniesPrecigen (NASDAQ:PGEN) CEO Helen Sabzevari Sells 119,250 SharesJune 3 at 4:04 AM | americanbankingnews.comPrecigen (NASDAQ:PGEN) Insider Donald Lehr Sells 29,131 SharesJune 2 at 4:58 AM | insidertrades.comPrecigen, Inc. (PGEN) is a Great Momentum Stock: Should You Buy?June 1 at 1:02 PM | zacks.comHC Wainwright Has Bullish Forecast for Precigen Q3 EarningsJune 1 at 1:20 AM | americanbankingnews.comPrecigen (NASDAQ:PGEN) Downgraded by Wall Street Zen to HoldMay 31 at 1:09 AM | americanbankingnews.comPrecigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 YearsMay 30, 2026 | prnewswire.comPrecigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United StatesMay 27, 2026 | prnewswire.comPrecigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare ConferenceMay 26, 2026 | prnewswire.comPrecigen (NASDAQ:PGEN) Stock Rating Upgraded by Wall Street ZenMay 23, 2026 | americanbankingnews.comPrecigen (PGEN): The Best Penny Stock to Buy for Long TermMay 22, 2026 | insidermonkey.comPrecigen: Why I Am More Cautious After The Q1 Beat (Downgrade)May 21, 2026 | seekingalpha.comEquities Analysts Set Expectations for Precigen Q3 EarningsMay 18, 2026 | marketbeat.comEarnings Beat: Precigen, Inc. (NASDAQ:PGEN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 16, 2026 | finance.yahoo.comPrecigen (NASDAQ:PGEN) Stock, Earnings Estimates, EPS, And RevenueMay 14, 2026 | benzinga.comPrecigen Earnings Call Highlights PAPZIMEOS Launch SurgeMay 14, 2026 | tipranks.comPrecigen IncMay 14, 2026 | edition.cnn.comPrecigen Inc (PGEN) Q1 2026 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...May 14, 2026 | finance.yahoo.comPrecigen’s lead cancer therapy is fueling a massive stock rally — here’s what Wall Street sees nextMay 14, 2026 | msn.comPrecigen jumps after Q1 beat as Papzimeos launch momentum takes holdMay 14, 2026 | msn.comPrecigen: Full Commercial Validation And Room To RunMay 14, 2026 | seekingalpha.comWhy is Precigen stock surging today?May 14, 2026 | za.investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLSI, PGEN, DMRA, and INBX Company DescriptionsDamora Therapeutics, Inc. Common Stock NASDAQ:DMRA$22.37 -0.58 (-2.53%) As of 03:57 PM EasternGalecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Greenwich LifeSciences NASDAQ:GLSI$24.29 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$23.92 -0.37 (-1.52%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Inhibrx Biosciences NASDAQ:INBX$95.22 +1.59 (+1.70%) Closing price 04:00 PM EasternExtended Trading$95.52 +0.30 (+0.31%) As of 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.Precigen NASDAQ:PGEN$3.81 -0.05 (-1.30%) Closing price 04:00 PM EasternExtended Trading$3.85 +0.04 (+1.05%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coke's $10B India IPO Plan Pops the Top on Hidden Value Palo Alto Networks Accelerates Growth 31% on AI Demand Motorola's $1.5B Bet to Own the Skies Microsoft Build 2026 Is Really Just One Big AI Stress Test FedEx Unboxes Billions in Post-Spinoff Value Slice of the Pie: Why Yum’s Deal Lifts QSR Urban Outfitters Stock Stalls Despite Another Strong Quarter What IBM's $10-Billion Quantum Project Means For Smaller Players Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
